Oncology

Caris Life Sciences and Flare to collaborate for oncology pipeline advancement

Caris Life Sciences and Flare Therapeutics have announced a partnership to advance the precision oncology pipeline of the latter into clinical trials.

TÜBITAK, MAM to produce drugs and vaccines on pilot scale in Türkiye

Marmara Research Center (MAM) and The Scientific and Technological Research Council of Türkiye (TÜBITAK) have commenced Medical Biotechnology Research Center (MEDIBIYO) for the production of drugs and vaccines on a pilot scale, reported Daily Sabah.

Mosaic Therapeutics raises $28m from Series A round to advance oncology therapies

UK-based oncology therapeutics company Mosaic Therapeutics has raised $28m from series A funding round.

FDA grants fast track status to Prestige’s PBP1510 for pancreatic cancer

The US Food and Drug Administration has granted fast track designation to Prestige Biopharma’s PBP1510 (Ulenistamab) to treat unresectable or metastatic pancreatic adenocarcinoma (PDAC).

Orion receives approval from Chinese NMPA for darolutamide

Orion has received approval from the Chinese National Medical Products Administration (NMPA) for darolutamide along with docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC) patients.

Evergreen Theragnostics raises $15m from Series B round

Evergreen Theragnostics, a clinical stage contract development and manufacturing organisation (CDMO), has completed capital raise of $15m from Series B round.

Sumitovant Biopharma completes acquisition of Myovant Sciences

Sumitovant Biopharma has closed the acquisition of Myovant Sciences in an all-cash deal with a total transaction value of around $1.7bn.

Volastra in-licenses Amgen’s KIF18A inhibitor sovilnesib

Volastra Therapeutics has concluded the in-licensing of Amgen’s oral, first-in-class small molecule KIF18A inhibitor, sovilnesib (AMG650).

Xspray Pharma and Eversana sign agreement for US launch of cancer therapy

Xspray Pharma and Eversana have signed an agreement for the launch and commercialisation of the former’s cancer therapy Dasynoc (XS004) in the US to treat chronic myeloid leukaemia (CML) and acute lymphatic leukaemia (ALL).